-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| A dose of "satellite-V" new crown vaccine can trigger a strong antibody response |
On July 13, a study published in Cell Reports Medicine , a journal of Cell Press, found that a single dose of the "Satellite-V" vaccine can trigger a significant antibody response against the new coronavirus
.
"Due to the limited supply and uneven distribution of vaccines in many regions of the world, local health bureaus urgently need data on vaccine immune response to optimize vaccination strategies
.
" Corresponding author of the paper, Fundación Leloir Institute in Buenos Aires, Argentina-Argentina National Andrea Gamarnik of the Science and Technology Research Council said, “Our peer-reviewed data provides information that can guide public health decision-making in response to the current global health emergency
Past studies have shown that the protective efficacy of two doses of "Satellite-V" against new coronary pneumonia is 92%
.
But an important question is, to protect more people faster, can a single dose achieve greater public health benefits than two doses
Evidence from other vaccines supports this single vaccination
.
The AstraZeneca vaccine shows 76% effectiveness after a single injection, while the Modena and Pfizer vaccines can induce sufficient immunity in previously infected individuals after a single injection, and an additional dose has no obvious benefit
In the new study, Gamarnik and his colleagues compared the new coronavirus-specific antibody response of 289 medical staff in Argentina after one injection and two injections of the "Satellite-V" vaccine
.
Three weeks after the second injection, all volunteers who had not previously been infected developed virus-specific immunoglobulin G (IgG) antibodies, the most common type of antibody in the blood
Within 3 weeks after receiving the first dose of the vaccine, 94% of the participants developed IgG antibodies, and 90% of the participants showed evidence of neutralizing antibodies
.
Other results showed that after a dose of the vaccine, the IgG and neutralizing antibody levels of participants who had previously been infected with the virus were significantly higher than those of fully vaccinated volunteers who had no history of infection
.
The second dose did not increase the neutralizing antibodies of volunteers with a history of infection
Gamarnik said: "This highlights the strong response of individuals with a history of infection after vaccination, indicating that naturally acquired immunity may be sufficiently enhanced with a single dose, which is consistent with recent mRNA vaccine research
.
"
People still need further research to evaluate the duration of the immune response, and to clarify the relationship between antibody levels and the protection of the new crown vaccine
.
Gamarnik said: "Evidence based on quantitative information will guide vaccine deployment strategies to deal with global vaccine supply constraints
Related paper information: http://dx.
http://dx.
doi.
org/10.
1016/j.
xcrm.
2021.
100359
